

# Volkmar Mueller

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9207498/publications.pdf>

Version: 2024-02-01

146  
papers

6,115  
citations

109321

35  
h-index

79698

73  
g-index

155  
all docs

155  
docs citations

155  
times ranked

8635  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	27.0	789
2	Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity. <i>Clinical Cancer Research</i> , 2005, 11, 3678-3685.	7.0	372
3	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	1.6	331
4	Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. <i>Oncotarget</i> , 2014, 5, 9650-9663.	1.8	304
5	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1378.	7.1	300
6	Breast cancer brain metastases: biology and new clinical perspectives. <i>Breast Cancer Research</i> , 2016, 18, 8.	5.0	226
7	Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 16923-16935.	1.8	207
8	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). <i>Lancet Oncology</i> , The, 2013, 14, 244-248.	10.7	172
9	Prognostic impact of circulating tumor cells assessed with the CellSearch System <sup>®</sup> and AdnaTest Breast <sup>®</sup> in metastatic breast cancer patients: the DETECT study. <i>Breast Cancer Research</i> , 2012, 14, R118.	5.0	160
10	Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. <i>BMC Medicine</i> , 2018, 16, 179.	5.5	134
11	Changes in Keratin Expression during Metastatic Progression of Breast Cancer: Impact on the Detection of Circulating Tumor Cells. <i>Clinical Cancer Research</i> , 2012, 18, 993-1003.	7.0	130
12	Exosomal microRNA as tumor markers in epithelial ovarian cancer. <i>Molecular Oncology</i> , 2018, 12, 1935-1948.	4.6	125
13	Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e75038.	2.5	114
14	Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. <i>British Journal of Cancer</i> , 2015, 113, 1358-1366.	6.4	110
15	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 61-68.	2.5	108
16	BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2281-2287.	1.6	86
17	Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. <i>Clinical Cancer Research</i> , 2017, 23, 5384-5393.	7.0	85
18	Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer. <i>Molecular Oncology</i> , 2019, 13, 1137-1149.	4.6	84

#	ARTICLE	IF	CITATIONS
19	Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. <i>EMBO Molecular Medicine</i> , 2020, 12, e11908.	6.9	77
20	Disseminated Tumor Cells Persist in the Bone Marrow of Breast Cancer Patients through Sustained Activation of the Unfolded Protein Response. <i>Cancer Research</i> , 2015, 75, 5367-5377.	0.9	70
21	Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients. <i>Scientific Reports</i> , 2018, 8, 12974.	3.3	59
22	Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. <i>OncImmunity</i> , 2019, 8, e1674605.	4.6	59
23	Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells. <i>Oncotarget</i> , 2017, 8, 56066-56080.	1.8	56
24	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 154-160.	2.2	56
25	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors â€” Data from the German PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 42-51.	2.2	54
26	Clonality of circulating tumor cells in breast cancer brain metastasis patients. <i>Breast Cancer Research</i> , 2019, 21, 101.	5.0	54
27	Frequent detection of <i>PIK3CA</i> mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer. <i>Molecular Oncology</i> , 2016, 10, 1330-1343.	4.6	53
28	Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer. <i>British Journal of Cancer</i> , 2018, 118, 847-856.	6.4	49
29	Patterns of distant metastases in vulvar cancer. <i>Gynecologic Oncology</i> , 2016, 142, 427-434.	1.4	47
30	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. <i>Breast Care</i> , 2020, 15, 294-309.	1.4	47
31	Suppression of Early Hematogenous Dissemination of Human Breast Cancer Cells to Bone Marrow by Retinoic Acid-Induced 2. <i>Cancer Discovery</i> , 2015, 5, 506-519.	9.4	45
32	Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R71.	5.0	44
33	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. <i>Cancers</i> , 2019, 11, 10.	3.7	43
34	Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer â€” Association With Patient and Disease Characteristics and Effect on Prognosis. <i>Journal of Clinical Oncology</i> , 2021, 39, 1619-1630.	1.6	39
35	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. <i>European Journal of Cancer</i> , 2021, 155, 1-12.	2.8	39
36	AKT3 regulates ErbB2, ErbB3 and estrogen receptor $\beta$ expression and contributes to endocrine therapy resistance of ErbB2+ breast tumor cells from Balb-neuT mice. <i>Cellular Signalling</i> , 2014, 26, 1021-1029.	3.6	37

#	ARTICLE	IF	CITATIONS
37	Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 924, 3-8.	1.6	37
38	Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positivestudy. <i>European Journal of Cancer</i> , 2019, 114, 76-88.	2.8	37
39	A Versatile Microarray Platform for Capturing Rare Cells. <i>Scientific Reports</i> , 2015, 5, 15342.	3.3	36
40	Cyclin D1 gene amplification is highly homogeneous in breast cancer. <i>Breast Cancer</i> , 2016, 23, 111-119.	2.9	33
41	Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. <i>Aging</i> , 2019, 11, 7796-7804.	3.1	33
42	Recent translational research: circulating tumor cells in breast cancer patients. <i>Breast Cancer Research</i> , 2006, 8, 110.	5.0	32
43	Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. <i>International Journal of Cancer</i> , 2015, 137, 2981-2988.	5.1	31
44	p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. <i>Oncotarget</i> , 2016, 7, 81322-81331.	1.8	31
45	Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. <i>Anticancer Research</i> , 2006, 26, 1479-87.	1.1	30
46	Potential Involvement of Jagged1 in Metastatic Progression of Human Breast Carcinomas. <i>Clinical Chemistry</i> , 2016, 62, 378-386.	3.2	29
47	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853.	4.5	29
48	Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 633-644.	1.8	28
49	The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 93-104.	2.5	28
50	Circulating Mitochondrial DNA is Linked to Progression and Prognosis of Epithelial Ovarian Cancer. <i>Translational Oncology</i> , 2019, 12, 1213-1220.	3.7	28
51	Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients. <i>Cancers</i> , 2020, 12, 442.	3.7	28
52	Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives. <i>Breast Cancer Research</i> , 2004, 6, 258-61.	5.0	27
53	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 59-65.	2.5	27
54	The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. <i>Scientific Reports</i> , 2019, 9, 2318.	3.3	27

#	ARTICLE	IF	CITATIONS
55	Characterizing death acceptance among patients with cancer. <i>Psycho-Oncology</i> , 2019, 28, 854-862.	2.3	27
56	CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6993.	4.1	26
57	Evaluation of a program for routine implementation of shared decision-making in cancer care: study protocol of a stepped wedge cluster randomized trial. <i>Implementation Science</i> , 2018, 13, 51.	6.9	25
58	High homogeneity of MMR deficiency in ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 669-675.	1.4	24
59	Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer. <i>BMC Cancer</i> , 2018, 18, 295.	2.6	23
60	Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 246-259.	1.8	23
61	Management of Patients with Brain Metastases Receiving Trastuzumab Treatment for Metastatic Breast Cancer. <i>Onkologie</i> , 2011, 34, 304-308.	0.8	22
62	Immature O-glycans recognized by the macrophage glycoreceptor CLEC10A (MGL) are induced by 4-hydroxy-tamoxifen, oxidative stress and DNA-damage in breast cancer cells. <i>Cell Communication and Signaling</i> , 2019, 17, 107.	6.5	21
63	Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1615.	4.1	20
64	Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 237-245.	1.8	20
65	Update Breast Cancer 2017 – Implementation of Novel Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1281-1290.	1.8	19
66	Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1079-1089.	1.8	18
67	Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression. <i>Oncotarget</i> , 2015, 6, 26789-26803.	1.8	18
68	Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 211.	2.8	16
69	Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review. <i>Breast Care</i> , 2017, 12, 168-171.	1.4	16
70	Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. <i>Scientific Reports</i> , 2017, 7, 17307.	3.3	16
71	Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1090-1099.	1.8	16
72	ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. <i>Future Oncology</i> , 2019, 15, 2211-2225.	2.4	16

#	ARTICLE	IF	CITATIONS
73	Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. <i>Breast Cancer Research</i> , 2019, 21, 60.	5.0	16
74	Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 403-414.	2.5	16
75	Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 602.	4.1	15
76	A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. <i>Molecular Carcinogenesis</i> , 2019, 58, 2306-2315.	2.7	14
77	Perceived relatedness, death acceptance, and demoralization in patients with cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 2693-2700.	2.2	14
78	Emerging Insights into Keratin 16 Expression during Metastatic Progression of Breast Cancer. <i>Cancers</i> , 2021, 13, 3869.	3.7	14
79	Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 3117-3128.	1.1	14
80	Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer. <i>Breast Care</i> , 2017, 12, 165-167.	1.4	12
81	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. <i>International Journal of Cancer</i> , 2019, 145, 857-868.	5.1	12
82	Adaptation and qualitative evaluation of encounter decision aids in breast cancer care. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1141-1149.	1.7	12
83	Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. <i>Cancers</i> , 2020, 12, 2787.	3.7	12
84	A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer. <i>Clinical Chemistry</i> , 2021, 67, 1395-1405.	3.2	12
85	Implementation analysis of patient reported outcomes (PROs) in oncological routine care: an observational study protocol. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 3.	2.4	11
86	Course of cervical intraepithelial neoplasia diagnosed during pregnancy. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1503-1512.	1.7	11
87	Demand for integrative medicine among women with breast and gynecological cancer: a multicenter cross-sectional study in Southern and Northern Germany. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 1315-1330.	1.7	11
88	Treatment With Etrinecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases. <i>JAMA Oncology</i> , 2022, , .	7.1	11
89	Immunological Approaches in the Treatment of Metastasized Breast Cancer. <i>Breast Care</i> , 2009, 4, 359-366.	1.4	10
90	In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non-water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines. <i>International Journal of Molecular Medicine</i> , 2016, 38, 1296-1302.	4.0	10

#	ARTICLE	IF	CITATIONS
91	Role of HYAL1 expression in primary breast cancer in the formation of brain metastases. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 427-438.	2.5	10
92	Psychosocial Distress in Women With Breast Cancer and Their Partners and Its Impact on Supportive Care Needs in Partners. <i>Frontiers in Psychology</i> , 2020, 11, 564079.	2.1	10
93	Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study. <i>Oncology Research and Treatment</i> , 2014, 37, 748-755.	1.2	9
94	Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). <i>European Journal of Cancer</i> , 2021, 153, 223-233.	2.8	9
95	Clinical Relevance of Disseminated Tumor Cells in the Bone Marrow and Circulating Tumor Cells in the Blood of Breast Cancer Patients. <i>Breast Care</i> , 2009, 4, 333-338.	1.4	8
96	Comparison of nine prognostic scores in patients with brain metastases of breast cancer receiving radiotherapy of the brain. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 325-332.	2.5	8
97	Dimensionality, Stability, and Validity of the Beck Hopelessness Scale in Cancer Patients Receiving Curative and Palliative Treatment. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 615-622.	1.2	8
98	Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. <i>Breast Care</i> , 2020, 15, 608-618.	1.4	8
99	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1005-1005.	1.6	8
100	<i>BRCA1</i> promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer. <i>Molecular Oncology</i> , 2021, 15, 3615-3625.	4.6	8
101	Insights into the Steps of Breast Cancer Brain Metastases Development: Tumor Cell Interactions with the Blood Brain Barrier. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1900.	4.1	8
102	Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial. <i>Cancers</i> , 2019, 11, 1186.	3.7	7
103	53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 930.	3.7	7
104	Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry Comparison of Three Different GPA Prognostic Scores. <i>Cancers</i> , 2021, 13, 844.	3.7	7
105	HER2 as marker for the detection of circulating tumor cells. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 535-537.	2.5	6
106	Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. <i>BMC Cancer</i> , 2018, 18, 541.	2.6	6
107	Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. <i>Cancers</i> , 2020, 12, 3021.	3.7	6
108	Cysteine-Rich Angiogenic Inducer 61: Pro-Survival Function and Role as a Biomarker for Disseminating Breast Cancer Cells. <i>Cancers</i> , 2021, 13, 563.	3.7	6

#	ARTICLE	IF	CITATIONS
109	Update Breast Cancer 2021 Part 5 â€œ Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2022, 82, 215-225.	1.8	6
110	Circulating Cellular Communication Network Factor 1 Protein as a Sensitive Liquid Biopsy Marker for Early Detection of Breast Cancer. Clinical Chemistry, 2022, 68, 344-353.	3.2	5
111	MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers, 2022, 14, 1721.	3.7	5
112	Update Breast Cancer 2021 Part 3 â€œ Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. Geburtshilfe Und Frauenheilkunde, 2021, 81, 654-665.	1.8	4
113	Update Breast Cancer 2021 Part 4 â€œ Prevention and Early Stages. Geburtshilfe Und Frauenheilkunde, 2022, 82, 206-214.	1.8	4
114	The Predictive Significance of Metastasis-Associated in Colon Cancer-1 (MACC1) in Primary Breast Cancer. Annals of Clinical and Laboratory Science, 2018, 48, 191-196.	0.2	4
115	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients â€œ a Survey Among Physicians. Geburtshilfe Und Frauenheilkunde, 2018, 78, 707-714.	1.8	3
116	MUC5AC expression is linked to mucinous/endometrioid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer. Pathology Research and Practice, 2021, 224, 153533.	2.3	3
117	High mitochondrial content is associated with breast cancer aggressiveness. Molecular and Clinical Oncology, 2021, 15, 203.	1.0	3
118	Detection and Characterization of Estrogen Receptor $\pm$ Expression of Circulating Tumor Cells as a Prognostic Marker. Cancers, 2022, 14, 2621.	3.7	3
119	Cerebral metastasis in recurrent squamous cell carcinoma of the vulva: case report and review of the literature. Archives of Gynecology and Obstetrics, 2020, 301, 327-332.	1.7	2
120	Development of a Short Instrument for Measuring Health-Related Quality of Life in Oncological Patients for Clinical Use: Protocol for an Observational Study. JMIR Research Protocols, 2020, 9, e17854.	1.0	2
121	Acceptance and Benefits of Two Different Strategies to Timely Integrate Specialist Palliative Care into Routine Cancer Care: A Randomized Pilot Study. Oncology Research and Treatment, 2022, 45, 118-129.	1.2	2
122	Comparison of PapilloCheck and linear array to detect and differentiate human papillomaviruses in cervical and tonsillar smears from females with cervical intraepithelial lesions. European Journal of Microbiology and Immunology, 2018, 8, 107-111.	2.8	1
123	Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?. Cancer Management and Research, 2018, Volume 10, 5423-5431.	1.9	1
124	Brain Metastasis in Breast Cancer Patientsâ€œNeed for Improvement. Cancers, 2020, 12, 3190.	3.7	1
125	TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer. BMC Cancer, 2021, 21, 920.	2.6	1
126	Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8â€œ11, 2020. Breast Care, 2021, 16, 89-93.	1.4	1



#	ARTICLE	IF	CITATIONS
127	DETECT III/IV: Two combined clinical trials based on the phenotype of circulating tumor cells (CTCs).. Journal of Clinical Oncology, 2014, 32, TPS11132-TPS11132.	1.6	1
128	Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC).. Journal of Clinical Oncology, 2017, 35, 10068-10068.	1.6	1
129	A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).. Journal of Clinical Oncology, 2017, 35, TPS1107-TPS1107.	1.6	1
130	6q deletion is frequent but unrelated to patient prognosis in breast cancer. Breast Cancer, 2021, , 1.	2.9	1
131	DETECT III: A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients (pts) with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells (CTC).. Journal of Clinical Oncology, 2012, 30, TPS1146-TPS1146.	1.6	1
132	Effect of mast cells on efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b.. Journal of Clinical Oncology, 2017, 35, 11522-11522.	1.6	1
133	Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial.. Journal of Clinical Oncology, 2019, 37, 588-588.	1.6	1
134	ASCO 2020. Breast Care, 2020, 15, 433-436.	1.4	0
135	Highlights from the San Antonio Breast Cancer Symposium (SABCS) 2019. Breast Care, 2020, 15, 192-196.	1.4	0
136	CLRM-14. OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE 3B/4 STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH OR WITHOUT BASELINE BRAIN METASTASIS (BM) WITH PREVIOUSLY TREATED ADVANCED/METASTATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BREAST CANCER (HER2+ BC); DESTINY-BREAST12. Neuro-Oncology Advances, 2021, 3, iv4-iv4.	0.7	0
137	Expert Discussion: Immunotherapy in Breast Cancer – Ready for Prime Time?. Breast Care, 2021, 16, 188-191.	1.4	0
138	Biomarq: A novel approach to automated HER2-analysis of circulating tumor cells (CTCs).. Journal of Clinical Oncology, 2013, 31, 638-638.	1.6	0
139	A novel approach to assess Her2-status of circulating tumour cells (CTCs) using the automated BioMarQ System.. Journal of Clinical Oncology, 2015, 33, e11615-e11615.	1.6	0
140	The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs).. Journal of Clinical Oncology, 2015, 33, TPS11109-TPS11109.	1.6	0
141	Discordance between HER2-phenotype on circulating tumor cells and primary tumor in women with advanced breast cancer.. Journal of Clinical Oncology, 2015, 33, 11003-11003.	1.6	0
142	Changes in circulating tumor cell counts during the course of chemotherapy in women with high-risk early breast cancer.. Journal of Clinical Oncology, 2016, 34, 11529-11529.	1.6	0
143	Quality of patient-reported outcome for long-term survival of early breast cancer trials.. Journal of Clinical Oncology, 2016, 34, e18121-e18121.	1.6	0
144	ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).. Journal of Clinical Oncology, 2017, 35, TPS1120-TPS1120.	1.6	0

#	ARTICLE	IF	CITATIONS
145	ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).. Journal of Clinical Oncology, 2018, 36, TPS1111-TPS1111.	1.6	0
146	Abstract OT2-26-01: Open-label, multinational, multicenter, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC): DESTINY-Breast12. Cancer Research, 2022, 82, OT2-26-01-OT2-26-01.	0.9	0